Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeDepreciation & Amortization - TotalEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Equity IncomeGross ProfitIncome from Continuing OperationsIncome from Non-Controlling InterestsIncome towards Parent CompanyInterest & Investment IncomeNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares OutstandingShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

DocGo (DCGO) EBITDA (2020 - 2025)

DocGo (DCGO) has 6 years of EBITDA data on record, last reported at -$28.1 million in Q3 2025.

  • For Q3 2025, EBITDA fell 536.16% year-over-year to -$28.1 million; the TTM value through Sep 2025 reached -$51.5 million, down 259.2%, while the annual FY2024 figure was $19.7 million, 159.52% up from the prior year.
  • EBITDA reached -$28.1 million in Q3 2025 per DCGO's latest filing, down from -$10.2 million in the prior quarter.
  • Across five years, EBITDA topped out at $23.4 million in Q4 2021 and bottomed at -$28.1 million in Q3 2025.
  • Average EBITDA over 5 years is $2.1 million, with a median of $3.6 million recorded in 2021.
  • Peak YoY movement for EBITDA: surged 173306.25% in 2021, then plummeted 536.16% in 2025.
  • A 5-year view of EBITDA shows it stood at $23.4 million in 2021, then tumbled by 63.32% to $8.6 million in 2022, then decreased by 3.94% to $8.2 million in 2023, then tumbled by 152.8% to -$4.4 million in 2024, then plummeted by 544.32% to -$28.1 million in 2025.
  • Per Business Quant database, its latest 3 readings for EBITDA were -$28.1 million in Q3 2025, -$10.2 million in Q2 2025, and -$8.9 million in Q1 2025.